New drug fights deadly superbug fungus
NCT ID NCT04148287
Summary
This study tested an experimental drug called APX001 for serious bloodstream and invasive infections caused by Candida auris, a dangerous and often drug-resistant fungus. The trial involved 9 adult patients who had limited treatment options with standard antifungal medications. Researchers measured whether the drug could clear the infection and monitored patients for side effects over about 10 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANDIDEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Milpark Academic Trauma Centre
Johannesburg, Gauteng, 2193, South Africa
-
Netcare Union Hospital Trauma Surgeons
Alberton, Gauteng, 1449, South Africa
Conditions
Explore the condition pages connected to this study.